Prof Adam Waldman
MRC Institute of Genetics & Molecular Medicine CANCER RESEARCH UK Imaging
The overall theme of my research is development and validation of quantitative and molecular imaging biomarkers which reflect key features of genetics and metabolism in human glioma, for clinical stratification, therapeutic planning and drug development:
Experimental phase MRI and PET imaging studies of intermediary metabolism, validated against tissue metabolic markers from defined tumour regions; for more reliable tumour characterisation, and identification of potential therapeutic targets.
Translational multi-centre platform studies of early therapeutic response in GBM using quantitative diffusion imaging for improved endpoints in clinical trials and clinical decision-making.
Quantitative MRI for treatment stratification and planning in adult supratentorial low grade glioma.
Development of PET-MRI methodology and co-analysis for improved glioma characterization.
Integration of quantitative MRI and PET into surgical neuro-navigation systems, for improved targeting for biopsy and surgical resection.
Biomarkers in Adult Glioma
EVEN MORE SEMINARS
Andy Rogers Nottingham University Hospitals
Interventional staff dose reduction: Gaining insight through new technology
Prof. Iris Grunwald Anglia Ruskin University, School of Medicine; Southend University Hospital
Pioneering treatment mechanical thrombectomy
Dr Ben Timmis 4ways Healthcare Ltd
How to manage x-ray reporting risk with fewer consultant radiologists
Mike Tanner EPSRC Proteus / Heriot-Watt University & University of Edinburgh
Locating medical devices through early arriving single photon imaging
Sanjay Prabhu, MBBS Harvard Medical School / Boston Children’s Hospital
Evolving role of machine learning in brain tumour imaging